BRPI0920959A2 - Inibidores de glicogênio sintase quinase-3 beta contendo derivados de 7-hidróxi-benzoimidazol-4-il-metanona - Google Patents
Inibidores de glicogênio sintase quinase-3 beta contendo derivados de 7-hidróxi-benzoimidazol-4-il-metanonaInfo
- Publication number
- BRPI0920959A2 BRPI0920959A2 BRPI0920959A BRPI0920959A BRPI0920959A2 BR PI0920959 A2 BRPI0920959 A2 BR PI0920959A2 BR PI0920959 A BRPI0920959 A BR PI0920959A BR PI0920959 A BRPI0920959 A BR PI0920959A BR PI0920959 A2 BRPI0920959 A2 BR PI0920959A2
- Authority
- BR
- Brazil
- Prior art keywords
- hydroxy
- derivatives
- metanone
- benzoimidazol
- beta inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 229920002527 Glycogen Polymers 0.000 title abstract 2
- 229940096919 glycogen Drugs 0.000 title abstract 2
- GGRAFBSODPLTOT-UHFFFAOYSA-N 7-hydroxy-1h-benzimidazole-4-carbaldehyde Chemical class OC1=CC=C(C=O)C2=C1N=CN2 GGRAFBSODPLTOT-UHFFFAOYSA-N 0.000 abstract 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 abstract 1
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11654308P | 2008-11-20 | 2008-11-20 | |
| PCT/JP2009/004975 WO2010058512A1 (en) | 2008-11-20 | 2009-09-29 | Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0920959A2 true BRPI0920959A2 (pt) | 2017-07-11 |
Family
ID=42197956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0920959A BRPI0920959A2 (pt) | 2008-11-20 | 2009-09-29 | Inibidores de glicogênio sintase quinase-3 beta contendo derivados de 7-hidróxi-benzoimidazol-4-il-metanona |
Country Status (15)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102170785A (zh) * | 2008-07-30 | 2011-08-31 | 肿瘤疗法科学股份有限公司 | 苯并咪唑衍生物和含有其的糖原合酶激酶-3β抑制剂 |
| CN101619058A (zh) * | 2009-01-08 | 2010-01-06 | 上海交通大学 | 一种苯并咪唑-4-酰胺型衍生物 |
| CA3134613A1 (en) | 2019-04-02 | 2020-10-08 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004065370A1 (en) * | 2003-01-23 | 2004-08-05 | Crystalgenomics, Inc. | Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof |
| TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| CN102271514A (zh) * | 2008-10-30 | 2011-12-07 | 肿瘤疗法科学股份有限公司 | 7-羟基-苯并咪唑-4-基-甲酮衍生物以及包含其的pbk抑制剂 |
-
2009
- 2009-09-29 KR KR1020117014051A patent/KR20110086750A/ko not_active Withdrawn
- 2009-09-29 SG SG2011036282A patent/SG171761A1/en unknown
- 2009-09-29 CN CN2009801549899A patent/CN102292083A/zh not_active Withdrawn
- 2009-09-29 EP EP09827294A patent/EP2358365A4/en not_active Withdrawn
- 2009-09-29 BR BRPI0920959A patent/BRPI0920959A2/pt not_active IP Right Cessation
- 2009-09-29 JP JP2011522179A patent/JP2012509249A/ja not_active Withdrawn
- 2009-09-29 RU RU2011124960/04A patent/RU2011124960A/ru unknown
- 2009-09-29 US US13/129,361 patent/US20110301146A1/en not_active Abandoned
- 2009-09-29 AU AU2009318719A patent/AU2009318719A1/en not_active Withdrawn
- 2009-09-29 MX MX2011005369A patent/MX2011005369A/es unknown
- 2009-09-29 WO PCT/JP2009/004975 patent/WO2010058512A1/en not_active Ceased
- 2009-09-29 CA CA2744012A patent/CA2744012A1/en not_active Abandoned
-
2011
- 2011-05-05 IL IL212704A patent/IL212704A0/en unknown
- 2011-05-19 CO CO11061830A patent/CO6361935A2/es not_active Application Discontinuation
- 2011-06-17 ZA ZA2011/04487A patent/ZA201104487B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110086750A (ko) | 2011-07-29 |
| JP2012509249A (ja) | 2012-04-19 |
| SG171761A1 (en) | 2011-07-28 |
| MX2011005369A (es) | 2011-06-20 |
| RU2011124960A (ru) | 2012-12-27 |
| ZA201104487B (en) | 2012-03-28 |
| CA2744012A1 (en) | 2010-05-27 |
| EP2358365A1 (en) | 2011-08-24 |
| US20110301146A1 (en) | 2011-12-08 |
| IL212704A0 (en) | 2011-07-31 |
| CO6361935A2 (es) | 2012-01-20 |
| AU2009318719A1 (en) | 2011-06-30 |
| CN102292083A (zh) | 2011-12-21 |
| EP2358365A4 (en) | 2012-05-30 |
| WO2010058512A1 (en) | 2010-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20110467A (es) | Derivados de benzofuranilo como inhibidores de la glucoquinasa | |
| SV2010003737A (es) | Derivados de indazol sustituidos con fenilo y benzodioxinilo | |
| UA107791C2 (en) | Pesticidal compositions | |
| EA201071032A1 (ru) | Гетероциклическое соединение | |
| BR112012010186A2 (pt) | derivados de heteroarila contendo n como inibidores de quinase jak3. | |
| MY153915A (en) | Organic compounds | |
| MX2009003834A (es) | Derivados de pirrolidina como inhibidores de iap. | |
| MA33803B1 (fr) | Inhibiteur de bromodomaine de benzodiazépine | |
| BRPI0816911A8 (pt) | Processo para preparação de 4-aminobut-2-enolidas | |
| CO6220968A2 (es) | Inhibidores heterociclicos de la aspartil proteasa | |
| PL2126020T3 (pl) | Hydrofobowo modyfikowane polialkilenoiminy jako inhibitory przenoszenia barwnika | |
| ECSP11010812A (es) | Complejo de mineral-aminoácido polisacárido | |
| BR112012026147A2 (pt) | espiroderivados azacíclicos como inibidores de hsl | |
| CL2012003104A1 (es) | Compuestos derivados de multiheteroarilos, inhibidores de prostaglandina d sintasa hematopoyetica (h-pgds); y composicion farmaceutica que los comprende. | |
| JO3577B1 (ar) | صيغ صيدلانية تشمل مشتقات 1-(بيتا-d- غلوكوبيرانوسيل) -2-ثينيل ميثيل بنزين كمثبطات sglt | |
| AR112787A2 (es) | Compuestos 1,5-difenil-penta-1,4-dien-3-ona | |
| BR112015001890A2 (pt) | inibidores de aril lactama quinase | |
| GT200800251A (es) | Nitrilos espirociclicos como inhibidores de proteasa | |
| PA8792401A1 (es) | Fenilendiaminas | |
| IN2013CH06133A (cg-RX-API-DMAC7.html) | ||
| EP2303018A4 (en) | SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE-INHIBITOR COMPOUNDS | |
| BR112013003059A2 (pt) | processo para preparar composto 2-hidroxifenil alquenil benzotriazol e processo para preparar compostos siloxano contendo função 2-hidroxifenil benzotriazol | |
| CO6321288A2 (es) | Sales de compuestos inhibidores de vih | |
| NZ700356A (en) | Pyrazole compounds as sglt1 inhibitors | |
| NO20081207L (no) | Isoquinolines as IGF-1R inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |